top of page


Age Management of West Michigan

Integrative Medicine

Conventional, Functional, and Anti-Aging Regenerative Medicine located in Grand Rapids, MI.
Dr. Shahnaz Ali            Dr. Piyush Bhatnagar


Bremelanotide offers a wide range of potential benefits, including improving sexual health, promoting weight loss, and enhancing cognitive health. It also contributes to improved blood sugar levels, a better lipid profile, mood enhancement, and increased energy levels. Additionally, it exhibits positive effects on eye health, aids in alcohol addiction treatment, and boosts immune function, making it a versatile compound with multiple potential advantages.

PT 141 / Bremelanotide

Bremelanotide (PT 141) is a melanocortin receptor agonist agent that has demonstrated efficacy in improving both female Hypoactive Sexual Desire Disorder and male erectile disorder and hypoactive sexual dysfunction.  PT 141 works directly on brain and nervous system by activating melanocortin 1-5 (MC1-5R) receptors. 

In females, PT 141 stimulates MC4R receptors involved in sexual arousal and response.   This stimulates the release of dopamine to brain areas that are involved in regulating the motivation and arousal of sexual behavior.   PT 141 has been shown in clinical trials to effectively treat HSDD (Hypoactive Sexual Desire Disorder) in both pre and post-menopausal women.  PT 141 has also shown in clinical trials to assist females in obtaining climax and obtaining a 50% increased satisfaction with sexual intercourse.

In Males, PT 141 acts on MC3R and MC4R to help treat erectile dysfunction and increase sexual arousal.   PT 141 works on the central nervous system instead of the vascular system like most ED drugs that are PDE5 inhibitors.  Clinical studies showed that PT 141 increased erections in 80% of men who do not respond to Viagra or Cialis.  

PT 141 / Bremelanotide Benefits

  • Improved sexual performance

  • Increase in libido, sexual desire, and sexual arousal

  • Elevated degree of sexual gratification and orgasm

  • Increased erections and erectile strength

  • Improved Mood and Energy

  • Promotes weight loss

  • Improve cognitive health

  • Improve blood sugar levels and lipid profile

  • Improve eye health

  • Treat alcohol addiction

  • Boost immune function

PT 141  Administration

PT 141 is administered sublinqual mouth spray (5 to 10 sprays) a minimum of one to two hours prior to sexual activity.   Benefits of PT 141 can last up to 72 hours.   It is recommended to administer PT 141 a maximum of 3 to 4 x weekly .

PT 141 is not recommended for the following people or conditions.

  • Cardiovascular disease / Heart disease (recommend physician approval)

  • Uncontrolled Hypertension / High Blood Pressure

  • Kidney Disease

  • Liver Disease

  • Pregnant or Breast Feeding

PT 141 is not recommended to be used with the following medications:

  • Naltrexone

  • Indomethacin


Individual results vary.  Best results obtained with combination of a healthy diet and lifestyle .   These products nor the ingredients have been approved or endorsed by the FDA.  These products are not intended to diagnose, treat, cure or prevent any disease.   Homeopathic products have not been reviewed by the FDA for safety and effectiveness to diagnose, treat, cure, or prevent any disease or conditions.  These are compounded for human use by a US 503A compounding pharmacy that provides these on patient-specific use as a dietary supplement.   You should consult a licensed health care professional before starting any supplement, dietary, or exercise program.  Products not recommended if you are pregnant or breast feeding.

Schedule your
Research and References

1.  Clayton AH, Althof SE, Kingsberg S, et al. Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial. Women’s Health. 2016;12(3):325-337.  doi:10.2217/whe-2016-0018.

2.  Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. The journal of sexual medicine. 2006; 3(4):628-638.

3.  Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences. 2003; 994:96-102. Retrieved from

4.  Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. International journal of impotence research. 2004; 16(2):135-42

5.  Shadiack AM, Sharma SD, Earle DC, Spana C, Hallam TJ. Melanocortins in the treatment of male and female sexual dysfunction. Curr Top Med Chem. 2007;7(11):1137-44.

6.  Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for theTreatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019 Nov;134(5):899-908. doi: 10.1097/AOG.0000000000003500. PMID: 31599840; PMCID: PMC6819021.

7.  Edinoff AN, Sanders NM, Lewis KB, Apgar TL, Cornett EM, Kaye AM, Kaye AD. Bremelanotide for Treatment of Female Hypoactive Sexual Desire. Neurol Int. 2022 Jan 4;14(1):75-88. doi: 10.3390/neurolint14010006. PMID:35076581; PMCID: PMC8788464.

8.  Kievit P, Halem H, Marks DL. Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques. Diabetes. 2013; 62(2):490-7

9.  Emmerson PJ, Fisher MJ, Yan LZ, Mayer JP. Melanocortin-4 receptor agonists for the treatment of obesity.  Current topics in medicinal chemistry. 2007; 7(11):1121-30.

10.  Spana, C., Jordan, R., & Fischkoff, S. (2022). Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials. Diabetes, obesity & metabolism, 24(6), 1084–1093.

11.  Zhou L, Sutton GM, Rochford JJ, et al. Serotonin 2C Receptor Agonists Improve Type 2 Diabetes via Melanocortin-4 Receptor Signaling Pathways. Cell Metabolism. 2007;6(5):398-405.

12.  Nogueiras R, Wiedmer P, Perez-Tilve D, et al. The central melanocortin system directly controls peripheral lipid metabolism. The Journal of Clinical Investigation. 2007;117(11):3475-3488. doi:10.1172/JCI31743.

13.  Maisto R, Gesualdo C, Trotta MC. Melanocortin receptor agonists MCR1-5 protect photoreceptors from high-glucose damage and restore antioxidant enzymes in primary retinal cell culture. Journal of cellular and molecular medicine. 2017; 21(5):968-974.

14.  Olney JJ, Sprow GM, Navarro M, Thiele TE. The protective effects of the melanocortin  receptor (MCR) agonist, melanotan-II (MTII), against binge-like ethanol drinking are facilitated by deletion of the MC3 receptor in mice. Neuropeptides. 2014;48(1):47-51. doi:10.1016/j.npep.2013.11.001

15.  Getting SJ, Flower RJ, Perretti M. Agonism at melanocortin receptor type 3 on macrophages inhibits neutrophil influx. Inflammation research : official journal of the European Histamine Research Society … [et al.]. 1999; 48 Suppl 2:S140-1.

bottom of page